cancer Cancer Discovery

Liver Transplant Patients Have Higher Prevalence of Colon Cancer and Non-Hodgkin Lymphoma

 Liver transplant patients over time experience an increasing trend toward colon cancer and non-Hodgkin lymphoma, according to an award-winning study led by a Loyola Medicine gastroenterologist. The study by Ayokunle Abegunde, MD, MSc, and colleagues also found that lung and heart transplant patients have a higher trend toward non-melanoma skin cancer. Dr. Abegunde was the senior author of the study, presented during the American College of Gastroenterology annual conference in Philadelphia.
Biotechnology

Hopkins Researchers Use Endoscope to Deliver Gene Therapy in Animal Study

Fixing or replacing faulty genes has emerged as a key to unlocking cures for numerous devastating diseases. But if the new, engineered genes can’t find their way into the patient’s genomic sequence, they won’t help. Johns Hopkins gastroenterologists Florin Selaru and Vivek Kumbhari believe they’ve taken a major step in the direction of helping patients with certain liver disorders by using an increasingly common endoscopic procedure to deliver therapeutic genes to the liver via
cancer Cancer Discovery

New Study Brings Hope to Liver Cancer Patients

Kandice Fogle, 43, had just moved to Houston when she began experiencing pain in her back and groin. After undergoing a CT scan, doctors found a large mass in her liver. A biopsy confirmed that she had intrahepatic cholangiocarcinoma, more commonly known as bile duct cancer. After having the mass removed and undergoing chemotherapy and radiation treatment, her cancer returned six months later. Frightened that she would not live to
Biotechnology

Maternal High-Fat Diet May Increase Offspring Risk for Liver Disease

Research could uncover who is most at risk for nonalcoholic fatty liver disease and lead to new treatments for this increasingly common condition Nonalcoholic fatty liver disease, a condition where fat builds up in the liver, is now the most common chronic liver disease diagnosed in adults and children. Although the disease is linked with obesity, scientists don’t fully understand why some people develop it and others don’t. Findings from
cancer Diabetes

Liver Cancer Drug Shows Promise in Preventing Liver Fibrosis and Treating NASH

Namodenoson, a Phase II drug developed by Can-Fite BioPharma Ltd. (NYSE MKT: CANF), has shown in newly published data that it prevents liver (hepatic) fibrosis progression in preclinical studies. "These latest study results add to the growing body of data that demonstrate Namodenoson's potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), indications for which there is currently no FDA approved drug. We are
cancer Diagnostic Testing Hepatitis

Liver Cancer Drug May Treat NASH, a Disease Projected to Reach Epidemic Proportions

There is no U.S. FDA approved therapy on the market today for Nonalcoholic steatohepatitis (NASH), a chronic liver disease found in adults and children. Between 5.6 and 8.4 million Americans are living with NASH today and this number is expected to jump to 25 million by 2025, driven by rising obesity rates. NAFLD, the liver disease which is a precursor to NASH, afflicts an estimated 30 million people today. These
Diagnostic Testing Hepatitis

Technique May Identify Patients With Fast-Progressing Fibrosis In Nonalcoholic Fatty Liver Disease

Combining multiple non-invasive measures, researchers at University of California San Diego School of Medicine describe a novel method to quantify the progression of nonalcoholic fatty liver disease (NAFLD) to its more dangerous and deadly states — advanced fibrosis and cirrhosis. The findings are published in the Oct 5 online issue of Hepatology. Roughly one-quarter of all Americans — an estimated 100 million adults and children — have NAFLD, which occurs